Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection

Li, Chenxi; Hall, Thomas G; Hall, John; He, Wenqiang

doi:10.1017/s0950268823000213

Cited by 2 publications

(2 citation statements)

References 37 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar dramatic declines in hepatocellular carcinoma incidence have been observed after initiation of HBV newborn vaccination programs globally from Gambia to Thailand. These data clearly demonstrate the population-level cancer prevention benefits achievable when effective viral vaccines are administered early and broadly to intercept oncogenic infection [19].…”

Section: Efficacy In Preventing Cancer By Blocking Infectionmentioning

confidence: 65%

Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions

Addissouky,

El Tantawy El Sayed,

Ali

et al. 2023

J Cell Immunol

View full text Add to dashboard Cite

Background: Cancer remains a leading cause of mortality with modest declines, highlighting the need for more efficacious prevention strategies like early immunological intervention against premalignant disease. Main body of abstract: Oncogenic viruses demonstrate prophylactic vaccines can successfully reduce malignancy by blocking precipitating infections. However, most cancers lack viral etiology, requiring novel approaches targeting sporadic precancerous states to enable early immunoprevention. Preneoplastic tissues exhibit biological changes making them appealing targets for stimulating immune surveillance before additional mutations cause unconstrained proliferation. High-risk precancers also provide sources of dysregulated self-antigens. Yet challenges exist in lesion identification, overcoming tolerance, and avoiding inflammation potentially worsening progression. Multidisciplinary insights into precancer immunology, predictive biomarkers, antigen discovery, and combinatorial vaccination strategies are illuminating rational vaccine design. Despite obstacles, prophylactic immunization against early dysplastic changes holds disruptive potential if key steps advance this approach. Elucidating preneoplasia immunobiology and progression risk modeling will be critical to guide productive immune targeting while mitigating immunotherapy hazards. Thoughtful translation could eventually shift paradigms by priming immunosurveillance against peak vulnerability lesions. Short Conclusion: Advancements in precancer vaccines may profoundly expand prevention horizons. Cautious immune targeting of premalignant states could intercept progression toward widely disseminated malignancies. This warrants methodical efforts to unravel the promise of thwarting lethal cancers before they start.

show abstract

Section: Efficacy In Preventing Cancer By Blocking Infectionmentioning

confidence: 65%

Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions

Addissouky,

El Tantawy El Sayed,

Ali

et al. 2023

J Cell Immunol

View full text Add to dashboard Cite

show abstract

“…It is also critical to check genotypes not targeted by the HPV vaccine. Li C et al reported a prevalence of high-risk non-vaccine types of 25.4% and a prevalence of vaccine types of 9.3% [28] among females aged 18-35 who received the 4vHPV vaccine, based on self-collected cervicovaginal samples. In a recent study [14], it was noted that although HPV-51 is not included in the 9vHPV vaccine, its prevalence has been decreasing, along with HPV 31, 33, and 39 over the last decade in Taiwan.…”

Section: Discussionmentioning

confidence: 99%

Genital Warts in Women Vaccinated against HPV in Childhood: A Systematic Review

Malheiro,

Magalhães,

Dias

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection among young women. Notably, more than ten years after the introduction of HPV vaccination programs in Europe, it is essential to review the real-world evidence of the incidence of anogenital warts (GWs) among women vaccinated during childhood. In this systematic review, three databases were searched for studies published between January 2008 and September 2023. Nine cohort studies were included. A total of 890,320 HPV-vaccinated women and 1,922,033 unvaccinated women were evaluated. All the studies but one investigated the 4vHPV vaccine. The incidence rate of GWs in vaccinated women ranged from 0.0 to 1650 per 100,000 person-years. The highest incidence rates were found in women vaccinated with one dose at the age of 17–19 years old and in fully vaccinated women only after 19 years of age. Similar incidence values were reported among unvaccinated women. The incidence of GWs was lower when the age at first dose was 9–11 years old. This systematic review reveals that the incidence of GWs among HPV-vaccinated women is related to the age of vaccination and the number of vaccine doses received. In the post-vaccination era, epidemiological surveillance of the incidence of GWs and their genotypes is crucial.

show abstract

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection

Cited by 2 publications

References 37 publications

Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions

Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions

Genital Warts in Women Vaccinated against HPV in Childhood: A Systematic Review

Contact Info

Product

Resources

About